**JCM Accepted Manuscript Posted Online 12 February 2021 J Clin Microbiol doi:10.1128/JCM.00110-21**

Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

**Copyright © 2021 Richard-Greenblatt et al.**

**This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.**

1. Title: Copan eNAT Transport System to Address Challenges in COVID-19 Diagnostics in
2. Regions with Limited Testing Access

3

4 Running title: eNAT transport medium for COVID-19 diagnostics

5

1. Melissa Richard-Greenblatta-c, Courtney E. Comard, Laurence Flevaude, Marina Bertie, Rebecca
2. M. Harrisa,c, Susan R. Weissd, Laurel Glasera,b#
3. aDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University
4. of Pennsylvania, Philadelphia, Pennsylvania, USA
5. bClinical Microbiology Laboratory, Hospital of the University of Pennsylvania, Philadelphia,
6. Pennsylvania, USA St. Joseph’s Healthcare, Hamilton, Ontario, Canada
7. cInfectious Disease Diagnostics Laboratory, Children’s Hospital of Philadelphia, Philadelphia,
8. Pennsylvania, USA
9. dDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania,
10. Philadelphia, Pennsylvania, USA
11. eMédicins Sans Frontières (MSF), Geneva, Switzerland
12. #Address correspondence to Laurel Glaser, [laurel.glaser@pennmedicine.upenn.edu](mailto:laurel.glaser@pennmedicine.upenn.edu)

18

19



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

# ABSTRACT

1. Community-based healthcare clinics and hospital outreach services have the potential to expand
2. coronavirus disease 2019 (COVID-19) diagnostics to rural areas. However, reduced specimen
3. stability during extended transport, the absence of cold chain to centralized laboratories, and
4. biosafety concerns surrounding specimen handling has limited this expansion. In the following
5. study, we evaluated eNAT (Copan Italia, Brescia, Italy) as an alternative transport system to
6. address the biosafety and stability challenges associated with expanding COVID-19 diagnostics
7. to rural and remote regions. In this study, we demonstrated that high titer severe acute respiratory
8. virus syndrome coronavirus 2 (SARS-CoV-2) lysate placed into eNAT medium cannot be
9. propagated in cell culture, supporting viral inactivation. To account for off-site testing in these
10. settings, we assessed the stability of contrived nasopharyngeal (NP) specimens stored for up to
11. 14 days in various transport medium (eNAT, eSwab, viral transport media [VTM], saline and
12. phosphate-buffered saline [PBS]) at 4°C, 22-25°C, and 35°C. Molecular detection of SARS-
13. CoV-2 was unaffected by sample storage temperature over the 2 weeks when stored in eNAT or
14. PBS (change in cycle threshold [Δ*CT*] ≤ 1). In contrast, variable stability was observed across test
15. conditions for other transport media. As eNAT can inactivate SARS-CoV-2, it may support
16. COVID-19 diagnostics at the point-of-care (POC). Evaluation of compatibility of eNAT with
17. Cepheid Xpert Xpress SARS-CoV-2 assay demonstrated equivalent diagnostic accuracy and
18. sensitivity compared to VTM. Taken together, these findings suggest that the implementation of
19. eNAT as a collection device has the potential to expand COVID-19 testing to areas with limited
20. healthcare access.

41

42

43



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

# INTRODUCTION

1. Infrastructure needed to comply with the World Health Organization (WHO) guidelines
2. for diagnostic laboratory workup for SARS-CoV-2 infection is limited in many parts of the
3. world. Consequently, testing is often centralized to laboratories based in cities with established
4. Biosafety Level-2 (BSL-2) facilities. The limited availability of testing facilities in rural and
5. remote regions has contributed significantly to disparities in SARS-CoV-2 testing (1-4).
6. Community-based healthcare clinics and hospital outreach services have the potential to expand
7. COVID-19 testing in rural areas. However, reduced specimen stability during extended transport,
8. the absence of cold chain to centralized laboratories and biosafety concerns during sample
9. collection and transport has limited this expansion (3, 4). Identifying strategies to expand testing
10. to areas with limited healthcare access is necessary to improve health outcomes and reduce
11. transmission in these communities.
12. Using an alternative transport system for COVID-19 diagnostics may improve access to
13. laboratory services by enhancing specimen stability and improving biosafety. The preferred
14. specimen for respiratory viruses has been an NP swab placed in universal VTM as the system is
15. able to preserve virus viability as well as support molecular diagnostics. In recent years,
16. respiratory virus detection has shifted almost entirely from viral culture to nucleic acid testing.
17. The transition in viral diagnostics has provided the opportunity to explore alternative transport
18. media types for COVID-19 diagnostics. Current Food and Drug Adminstration (FDA) guidance
19. recommends liquid Amies (eSwab), normal saline or PBS as alternative transport media for
20. COVID-19 diagnostic testing. However, manufacturers do not report the stability of viral nucleic
21. acid stored in these media types, and based on limited data available, the FDA recommends
22. storage of specimens for SARS-CoV-2 detection for up to 72 h at 4°C. In addition, limited



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. studies exist that assess alternative transport systems capable of inactivating the SARS-CoV-2
2. virus, enabling safe transport from rural and remote settings (5, 6). Immediate viral inactivation
3. upon collection may also permit the decentralization of COVID-19 testing from BSL-2 certified
4. laboratories and promote the use of platforms that can be deployed at the POC (7).
5. Inactivation methods involving the immersion of clinical samples in solution containing
6. the denaturant agent, guanidine thiocyanate, were implemented during past Ebola outbreaks to
7. increase testing capacity and reduce exposure risk in the analysis chain (8). In addition to Ebola,
8. other viruses can be inactivated by the agent (9, 10). Copan eNAT (Copan Italia, Brescia, Italy)
9. is an FDA-cleared commercially available transport system that combines a flocked swab with a
10. guanidine thiocyanate-based medium. The product is claimed to inactivate microorganisms
11. (Gram positive and Gram negative bacteria, yeasts and molds) as well as preserve nucleic acid
12. for molecular testing. However, limited data exist related to inactivation and nucleic acid
13. stability of viruses collected and stored in eNAT. Therefore, as a potential mechanism to reduce
14. risk associated with specimen handling and increase access to COVID-19 testing, the following
15. study evaluated eNAT as an alternative transport system for SARS-CoV-2 molecular testing.
16. The ability of eNAT to inactivate SARS-CoV-2, maintain viral RNA stability over time at
17. various temperatures (4-35°C), and demonstrate compatibility with Xpert Xpress SARS-CoV-2
18. assay (Cepheid, CA, USA) were assessed.

85

# MATERIALS AND METHODS

1. **Preparation of SARS-CoV-2 Stock.** SARS-CoV-2 (USA-WA1/2020 strain) was obtained from
2. BEI (NR-52281) and propagated in African green monkey kidney Vero-E6 cells (ATCC CRL-
3. 1586). The Vero-E6 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM;
4. Gibco catalog no. 11965), supplemented with 10% fetal bovine serum (FBS), 100 U/ml of



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. penicillin, 100 μg/ml streptomycin, 50 μg/ml gentamicin, 1mM sodium pyruvate, and 10mM
2. HEPES. SARS-CoV-2 stock (2.3 x 107 PFU/mL; corresponding to a C*T* value of 11.5 on a
3. laboratory-developed SARS-CoV-2 assay on the BD MAX system) was made by infecting Vero-
4. E6 cells at multiplicity of infection of 0.01 in serum-free DMEM for 1 hour at 37°C. After 1
5. hour, the inoculum was removed and replaced with 2% FBS DMEM. Cells were incubated for 3-
6. 4 days at 37°C, and once significant cytopathic effect was observed, the virus stock was
7. harvested. Stock was frozen/thawed one to two times, and then cellular debris removed by
8. centrifugation. Infectious virus concentration was determined by viral plaque assay as previously
9. described (11). The genomic RNA was sequenced and was determined to have 100% identity
10. with the expected strain (GenBank: MN985325.1).
11. **Inactivation of SARS-CoV-2 by eNAT.** Evaluation of viral inactivation by Copan eNAT
12. transport medium was performed by preparing mock upper respiratory tract specimens from
13. SARS-CoV-2 stock. Regular sized flocked swabs were dipped into 100 µl of SARS-CoV-2 stock
14. solution before being placed into a transport tube containing 1 mL of eNAT (Copan Italia, eNAT
15. 6C057N.RUO) or 1 mL of DMEM (positive control). In parallel, a negative control was prepared
16. by dipping a regular-sized flocked swab in 100ul of DMEM and placing it into a transport tube
17. containing 1 mL eNAT. All three mock specimen types were vortexed and then incubated at
18. room temperature (22-26°C) for 10 minutes. Data was gathered from three independent
19. experiments.
20. The presence of infectious particles was determined by viral plaque assay (11). Each
21. specimen type was 10-fold serially diluted to 10-6 starting with 50 µl of the original sample. The
22. dilutions were plated to Vero E6 cells and incubated for 1 h at 37°C. The inoculum was overlaid
23. with DMEM plus agarose (0.1%) and re-incubated for 72 hours at 37°C. Cells were fixed with



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. 4% paraformaldehyde and stained with 1% crystal violet. The viral titer of the mock samples was
2. determined by calculating plaque-forming units per milliliter (PFU/mL) based plaque counts. All
3. virus manipulations were conducted in a biosafety level 3 laboratory using approved personal
4. protective equipment and protocols.

# Comparison of molecular detection stability of SARS-CoV-2 in alternative transport media

1. **stored at various temperatures over 14 days.** Experiments were performed using residual NP
2. swab specimens collected in 3 mL of 0.9% saline previously characterized as SARS-CoV-2
3. positive in the Hospital of the University of Pennsylvania Clinical Microbiology Laboratory
4. (Xpert Xpress SARS-CoV-2, Cepheid). Five specimens were pooled (1 mL of each specimen) to
5. obtain sufficient volume for the stability studies. Specimens were selected if they were collected
6. <48 h prior to pooling, stored at 2-8°C, and had a cycle threshold (*CT*) value of <30 (Ct range 18
7. to 27) to avoid any loss in assay reproducibility when a signal occurred near the limit of
8. detection.
9. Samples were prepared in triplicate for each condition (4°C, 22-25°C, and 35°C) and
10. each transport medium tested. Therefore, a total of 9 samples were contrived for each type of
11. transport media. Transport media evaluated in these experiments included: universal VTM (BD
12. Diagnostics, MD, USA), eSwab (Copan Italia, Brescia, Italy), 0.9% saline (BD BBL Prepared
13. Saline Solution, MD, USA), phosphate-buffered saline (0.067 M, pH 6.8; Hardy Diagnostics,
14. CA, USA), and eNAT (Copan Italia, Brescia, Italy). Each contrived sample was prepared by
15. dipping a regular-sized flocked swab into the freshly prepared pooled saline and placing it into a
16. 15 mL polypropylene conical tube (Corning, AZ, USA) containing 3 mL of transport medium.
17. Due to limited reagent availability and allocations of Cepheid Xpert Xpress SARS-CoV-2
18. cartridges for our institutions, the stability of specimens for molecular detection of SARS-CoV-2



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. was measured using a laboratory-developed Emergency Use Authorized RT-PCR assay on the
2. BD Max System (BD Diagnostics, MD, USA). *CT* values for SARS-CoV-2 were determined at
3. baseline and compared to 1, 3, 7, and 14 day(s) of storage at 4°C, 22-25°C and 35°C. Based on
4. the BD MAX interassay precision (SARS-CoV-2 target *CT* range ±0.7), we considered a change
5. in *CT* (Δ*CT*) score from baseline (day 0) to be equivalent if ≤1.0 (12, 13), and a loss in
6. stability/sensitivity if an increase in *CT* of ≥1.1 was observed. As specimen stability is
7. independent of molecular platform used, the findings from these studies can be extended to the
8. POC.
9. **Compatibility of eNAT with Xpert Xpress SARS-CoV-2 assay.** To determine the
10. compatibility of eNAT with the Xpert SARS-CoV-2 assay, we compared the performance of
11. matched eNAT-VTM paired samples for the detection of SARS-CoV-2. Matched specimens
12. were contrived using previously characterized NP swab specimens collected in 0.9% saline
13. (n=20) collected within 48 h and stored immediately at 4°C following clinical testing. All
14. samples included were from the adult population at the Hospital of the University of
15. Pennsylvania. To ensure the accuracy studies encompassed the Xpert Xpress SARS-CoV-2 assay
16. detection range, all previously characterized positive samples were screened and selected for
17. based on C*T* value. Five samples were collected for each of the following *CT* ranges: (i) C*T* value
18. ≤25, (ii) C*T* value 26-29, (iii) C*T* value ≥30. Each specimen was prepared by dipping a flocked
19. swab into the clinical specimen and then placing it into 1 mL of the respective medium.
20. Specimens were vortexed and immediately run using the Cepheid Xpert Xpress SARS-CoV-2
21. assay according to manufacturer guidelines. Since data is not publicly available surrounding
22. interassay variability for the SARS-CoV-2 express assay, we used precision data from the
23. Children’s Hospital of Philadelphia Infectious Diseases Diagnostic Laboratory (n=58). The



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. interassay coefficient of variation was determined to be 1.3% for both targets. Ranges of 1.7 C*T*
2. and 1.9 C*T* were observed for the E gene and N2 gene, respectively. Therefore, we considered
3. any difference between paired specimen C*T* values >±2.0 to be significant.
4. Lastly, we investigated the impact of eNAT on the analytical sensitivity of the Xpert
5. Xpress SARS-CoV-2 assay. The assay has a claimed LoD of 250 copies/mL for NP swabs
6. collected in VTM. Based on the reported LoD, a dilution series (25, 125, 250, and 500
7. copies/mL) was performed in triplicate to determine if eNAT impacts analytical sensitivity.
8. Contrived specimens were prepared for each transport medium. Pooled saline from negative NP
9. swab collections (n=5) was added to eNAT or VTM at a dilution of 1:10. The spiked transport
10. medium was used to serially dilute SARS-CoV-2 positive material (SeraCare Life Sciences Inc.,
11. MA, USA). Each sample was run immediately using the Xpert Xpress SARS-CoV-2 assay.
12. **Statistical analysis.** Analysis for this study was performed using GraphPad Prism version 7.04
13. (San Diego, CA, USA). Comparison in sensitivity of collection methods (eNAT and VTM) for
14. detecting SARS-CoV-2 was performed using a paired t-test. Percent agreement of the collection
15. method was determined based on previous SARS-CoV-2 RT-PCR characterization by the
16. clinical laboratory. Kappa was calculated to quantify the degree of overall agreement between
17. the two transport media for the detection of SARS-CoV-2 using the Xpert Xpress assay.

# RESULTS

1. **Inactivation of infectious SARS-CoV-2 by eNAT.** Prior to evaluating the effectiveness of
2. eNAT inactivation of SARS-CoV-2, we investigated the cytotoxic effect of the transport medium



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. on Vero-E6 cells. Cell lysis was only observed in the first (10-1) of the dilution series. Based on
2. these findings, the limit of detectable virus was 500 PFU/mL.
3. Inactivation of infectious SARS-CoV-2 by eNAT was evaluated using contrived
4. specimens to mimic those obtained in the clinical laboratory. Following 10 minutes of incubation
5. at room temperature, no SARS-CoV-2 could be detected by standard viral plaque assay (Figure
6. 1A). In contrast, virus soaked swabs placed into serum-free DMEM had detectable amounts (4.4
7. x 105 PFU/mL) of infectious SARS-CoV-2 when quantified by plaque assay.
8. It was of interest to further increase the infectious virus concentration and dilution of
9. eNAT. Therefore, an equal volume of SARS-CoV-2 stock was combined with eNAT or DMEM
10. and placed at room temperature for 10 minutes prior to quantifying infectious virus particles.
11. Increasing concentration of infectious SARS-CoV-2 from 2.1 x 106 PFU/mL to 1.2 x 107
12. PFU/mL and diluting eNAT 1:1 did not impact its inactivation efficacy (Figure 1B). Therefore,
13. these findings suggest that specimens collected in Copan eNAT can inactivate infectious SARS-
14. CoV-2 at clinically relevant concentrations.

# Molecular detection stability of SARS-CoV-2 from swabs stored in different transport

1. **medium at different temperatures.** In low and middle-income countries (LMICs), clinical
2. sample transportation can take >7 days until receipt by the processing laboratories due to a lack
3. of well-established transportation networks (14, 15). These specimens are often transported by
4. motorbike resulting in challenges in maintaining a cold chain throughout the delivery process.
5. Similar challenges exist in developed countries where certain delivery methods result in breaks
6. in cold chain (e.g. mail-in samples), and specimens collected in rural areas may experience
7. delays in transport to centralized laboratories. To address specimen stability challenges related to
8. extended transport times and breaks in cold chain, we evaluated the molecular detection stability



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. of SARS-CoV-2 stored in eNAT to other transport media currently recommended for collection
2. of upper respiratory tract specimens (Figure 2). SARS-CoV-2 molecular detection remained
3. stable (Δ*CT* <1) for all transport media when stored at 4°C for the duration of the study period,
4. except for eSwab and VTM. Both transport media demonstrated a decreasing signal over time,
5. which reflected a small (Δ*CT* <2) but significant change in Δ*CT* from baseline at day 14.
6. At higher storage temperatures (room temperature and 35°C), reduced molecular
7. detection stability was observed for saline, eSwab, and VTM within the 14-day time period.
8. Temperature and length of storage demonstrated the greatest impact on SARS-CoV-2 RNA
9. recovery from the eSwab. A significant loss in detection was observed as early as day 3 and day
10. 1 of storage at 22°C and 35°C, respectively. Storage at 35°C showed the greatest loss in
11. sensitivity with a change of ~10 *CT* by day 7.
12. Compared to the eSwab, the effect of higher storage temperatures on SARS-CoV-2
13. detection from saline and VTM was not as extreme. At both 22°C and 35°C, *CT* values for
14. SARS-CoV-2 stored in saline gradually rose above the Δ*CT* significance threshold to reach a
15. maximum Δ*CT* from baseline of 2.3 ± 0.06 and 3.0 ± 0.2, respectively. A significant loss in
16. detection when stored in VTM at 22°C was only observed on day 14 (Δ*CT*, 1.6 ± 0.7); however,
17. at 35°C storage, a significant loss in detection was observed on both days 7 (Δ*CT*, 2.2 ± 0.5) and

221 14 (Δ*CT*, 4.9 ± 0.2).

1. Storage temperature and time did not appear to have any impact on SARS-CoV-2
2. detection for NP specimens stored in eNAT or PBS. Therefore, these findings suggest that eNAT
3. and PBS have utility for extended transport and that the reliability of a cold chain is
4. inconsequential when using these two types of transport media.



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. **Compatibility of eNAT with Cepheid Xpert Xpress SARS-CoV-2.** As we observed eNAT to
2. both inactivate SARS-CoV-2 and maintain viral RNA stability over time at various temperatures
3. (4-35°C), it was of further interest to evaluate the compatibility of the transport medium with
4. POC SARS-CoV-2 molecular diagnostics. Due to the wide distribution of the Cepheid
5. GeneXpert System in rural and remote regions globally, we assessed the impact of eNAT on the
6. analytical sensitivity and clinical accuracy of SARS-CoV-2 detection using the Xpert Xpress
7. SARS-CoV-2 assay. Twenty paired eNAT and VTM specimens (positive n=15; negative n=5)
8. contrived from previously characterized NP specimens demonstrated 100% overall agreement
9. (20/20 κ = 1.0) using the Xpert Xpress SARS-CoV-2 assay (Table 1). Of the 15 positive
10. specimen pairs tested, none were considered significantly different based on the SARS-CoV-2
11. cartridge interassay variability, suggesting that eNAT does not impact SARS-CoV-2 detection
12. when using the Xpert Xpress SARS-CoV-2 assay (Table 2).
13. To further confirm compatibility with the assay, we evaluated the effect of using eNAT
14. on assay analytical sensitivity. Contrived NP specimens prepared in eNAT or VTM from
15. previously characterized negative samples were spiked with varying concentrations of SARS-
16. CoV-2 positive control material (SeraCare) and run in triplicate (Table 3). We did not observe
17. any difference in detection (6/6 targets detected) at 2x the LoD or the 250 copies/mL assay LoD.
18. The same was true for specimens spiked with 125 copies/mL (6/6 targets detected); however,
19. there was a loss in detection of SARS-CoV-2 in both eNAT (4/6 targets detected) and VTM (3/6
20. targets detected) at 25 copies/mL. To further evaluate the impact of eNAT on assay sensitivity,
21. the mean C*T* values were compared for each concentration of the transport media pairs. The C*T*
22. values did not show statistically significant differences (*P* > 0.05). Therefore, eNAT exhibits



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

|  |  |
| --- | --- |
| 248 | equivalent performance for the detection of SARS-CoV-2 relative to VTM and is compatible for |
| 249 | use with the Cepheid Xpert Xpress SARS-CoV-2 assay. |
| 250 |  |
| 251 | **DISCUSSION** |
| 252 | Challenges surrounding biosafety and specimen stability has limited COVID-19 diagnostics |
| 253 | in rural and remote regions. A pragmatic approach for communities with limited access to testing |
| 254 | may be to implement transport media capable of inactivating SARS-CoV-2, enabling safe |
| 255 | movement of specimens from the point of collection to processing in a centralized laboratory. In |
| 256 | addition, a transport medium with nucleic acid stabilizing properties over a wide range of |
| 257 | temperatures (4-35°C) can extend testing access to regions that lack well-developed |
| 258 | transportation networks. Even with the potential to expand testing to underserved populations, |
| 259 | timely access to diagnosis in health systems with fragile specimen-transport logistics remains |
| 260 | problematic. Therefore, a transport medium capable of viral inactivation and nucleic acid |
| 261 | preservation has the potential to support molecular assays at POC and can, in turn, provide |
| 262 | earlier detection of SARS-CoV-2, leading to improvements in case management and contact |
| 263 | tracing. |
| 264 | Transport media currently implemented (e.g. VTM, saline, PBS) for the collection of swabs |
| 265 | can maintain viability of human coronaviruses for several days, including SARS-CoV-2 (5, 16- |
| 266 | 18). To reduce risk to personnel associated with the collection, transport, and processing of |
| 267 | specimens, it is necessary to use a transport medium capable of viral inactivation. Our plaque |
| 268 | reduction studies demonstrated high titers of SARS-CoV-2 to be inactivated within 10 minutes |
| 269 | of incubation with eNAT. These findings are in support of those previously described that have |
| 270 | shown inactivation of SARS-CoV-2 following 2 minutes (5) and 10 minutes (6) of incubation |
| 271 | with eNAT. In these studies, the ratio of eNAT to virus varied from our conditions. However, in |



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. all test conditions with reagent-to-virus ratios of equal volume or favoring eNAT (10:1, 5:1, 3:1),
2. none had virus detectable in titration. In contrast, Welch and colleagues (6) demonstrated that for
3. conditions where eNAT is diluted 1:3, eNAT concentrations are not sufficient to inactivate
4. SARS-CoV-2. Although specimen dilution of eNAT is an important consideration, Copan
5. collection devices are available in 1 mL and 2 mL eNAT volumes with flocked swab volume
6. uptake ~142 uL (19). Therefore, when using the device as described by the manufacturer, the
7. specimen would not dilute the reagent to concentrations suboptimal for SARS-CoV-2
8. inactivation.
9. We observed both eNAT and PBS to preserve molecular detection of SARS-CoV-2 over a
10. range of temperatures (4-35°C) throughout the 14-day evaluation period. To our knowledge, this
11. is the first study evaluating the stability of SARS-CoV-2 RNA in eNAT; however, similar results
12. at 4°C and room temperature (18-26°C) have been described for PBS previously (20-22). In
13. contrast, storage time and temperature had a variable impact on SARS-CoV-2 detection for
14. swabs stored in VTM, saline, or eSwab, especially when specimens were not refrigerated. These
15. findings suggest limited utility for VTM, saline, and eSwab for long-term transport of SARS-
16. CoV-2 specimens in the absence of a cold chain.
17. Considerable variability exists in the literature related to SARS-CoV-2 RNA stability in
18. alternative transport media. Factors associated with the preparation of contrived specimens for
19. these stability studies such as the volume of NP specimen spiked and host factors (nasal
20. microbiota, immune status, etc.), are likely to contribute to this variability. As differences in the
21. NP microbial communities have been reported among SARS-CoV-2-positve and –negative
22. patients (23), and unlike other studies (21, 22), we attempted to address this by using pooled
23. SARS-CoV-2 positive patient material to represent a more clinically accurate specimen type.



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. Furthermore, definitions as to what C*T* value increase is deemed significant for a loss in
2. sensitivity or stability is not standardized across studies. We based our interpretation of a loss of
3. sensitivity on the precision of the assay utilized for the stability studies. Our cut-off (> 1 C*T* value
4. increase) was more conservative than other studies (> 2 or 3 C*T* value increase) (20, 21).
5. Nonetheless, our findings suggest that eNAT offers greater stability for long-term
6. storage/transport, even in the absence of a cold chain, compared to VTM, saline, and eSwab.
7. Current guidance by the WHO and U.S. Centers for Disease Control and Prevention requires
8. testing of clinical specimens to be carried out in a BSL-2 setting. An exception to this is POC
9. testing or near-POC, where biosafety guidelines allow testing to be performed outside of a
10. biological safety cabinet if appropriate precautionary measures are in place. Chemical
11. inactivation at the time of specimen collection by the transport medium is the most practical for
12. POC workflows. Immediate chemical inactivation eliminates infectious aerosols or droplet
13. generation and thus reduces some of the operational requirements needed for safe handling of
14. infectious respiratory samples at the POC. Of additional benefit, chemical inactivation does not
15. require new equipment or cause delays in processing (e.g. heat inactivation). Although viral
16. inactivation is not mandated for POC testing, eNAT can minimize operational requirements (e.g.
17. additional personal protective equipment or splash shields) needed, ultimately improving
18. workflow and safety for COVID-19 molecular diagnostics at POC.
19. In 2010, the WHO endorsed GeneXpert MTB/RIF for the rapid diagnosis of tuberculosis,
20. leading to a massive scale-up of Xpert worldwide. Many high burden countries have adopted a
21. “hub-and-spoke” model for scale-up where Xpert instruments are placed at higher-level facilities
22. with adequate infrastructure (e.g. security, stable power) known as the hub, which receive
23. specimens from several lower-level health facilities (spokes). With this model, Xpert testing



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. services have increased access to rapid and more sensitive diagnostic testing for patients who
2. present to lower level health facilities in underserved areas. As eNAT demonstrated
3. compatibility with the Xpert Xpress SARS-CoV-2 assay, pairing this specimen transport device
4. with existing Xpert systems and infrastructure can support the expansion of COVID-19
5. diagnostics in underserved communities.
6. Our study has limitations. Despite having diluted out the cytotoxic effect of eNAT on Vero-
7. E6 cells, this resulted in a higher LoD (500 PFU/mL rather than 50 PFU/mL) for the assay. In
8. previous studies, removal of eNAT from treated SARS-CoV-2 was performed (e.g. buffer
9. exchange method or spin column filtration) before the addition of virus to plaque reduction
10. assays (5, 6). These cytotoxic mitigating techniques significantly improved assay sensitivity,
11. enabling the observation of complete inactivation of high titer virus (>107 PFU/mL) at 5:1
12. reagent to virus dilution (5). Although these findings do not allow us to conclude complete
13. inactivation of SARS-CoV-2 in our studies, it is likely that with improved assay sensitivity,
14. further reduction in viral titers would have been observed.
15. Another limitation is that the use of contrived specimens throughout the studies may have
16. underestimated the effect of possible RT-PCR inhibitors (i.e. bacterial and immune products) as
17. these would have been diluted out during sample preparation. However, unlike the other
18. transport medium evaluated, it is unlikely that the stability findings of eNAT would have been
19. impacted by this dilution effect due to its protein denaturation and bacterial inactivation
20. properties. As a results of limited reagent availability and institutional allocations, we were
21. unable to include additional VTM-eNAT sample pairs in the Xpert Xpress SARS-CoV-2
22. accuracy studies. Therefore, conclusions from our studies are based on a small number of NP
23. matrices and may not be generalizable to all NP specimens.



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. The current study solely focused on the performance of eNAT and its compatibility with the
2. Cepheid Xpert Xpress SARS-CoV-2 assay. Although our findings suggest that eNAT can be
3. used for COVID-19 diagnostics at the POC, additional evaluation is required for laboratories
4. using other nucleic acid amplification assays to ensure compatibility. Lastly, in-field validation
5. studies of the performance of eNAT with the Xpert Xpress SARS-CoV-2 assay are needed to
6. confirm the findings of this study.
7. In conclusion, we investigated eNAT as an alternative transport medium for the collection of
8. swabs for SARS-CoV-2 testing. Our findings suggest that eNAT is capable of inactivating
9. SARS-CoV-2 and can maintain specimen stability for an extended time, even in the absence of a
10. cold chain (i.e. 14 days at 35°C). Improvements in biosafety and specimen stability can support
11. collection of specimens in the community and transport to BSL-2 laboratories, ultimately
12. eliminating the challenge of the patient needing to travel to testing sites. However, for many
13. communities worldwide, delays in specimen transport to centralized testing centers is common,
14. translating to suboptimal turnaround times for test results. As eNAT can inactivate SARS-CoV-2
15. and is compatible with the Cepheid Xpert Xpress SARS-CoV-2 assay, COVID-19 diagnostic at
16. the POC becomes possible. Therefore, findings from this study suggest that eNAT may represent
17. a promising mechanism to improve access to COVID-19 diagnostic testing for communities with
18. limited healthcare access.

# ACKNOWLEDGEMENTS

1. We would like to acknowledge Santina Castriciano for her assistance in coordinating the study,
2. as well as Ashley Bergman, Linda Leach and Kevin Weller for their technical assistance.



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. eNAT specimen collection and transport devices used in this study were generously provided by
2. Copan Italia. This work was supported by the National Institutes of Health (Grant R01 AI140442
3. to S.R.W and C.E.C).
4. The authors have no conflicts of interest to disclose.

# DISCLAIMER

1. The views expressed are those of the authors and not necessarily those of Médicins Sans
2. Frontières (Doctors without Borders).

# REFERENCES

1. 1. Tan TQ, Kullar R, Swartz TH, Mathew TA, Piggott DA, Berthaud V. 2020. Location
2. Matters: Geographic Disparities and Impact of Coronavirus Disease 2019 (COVID-19). J
3. Infect Dis doi:10.1093/infdis/jiaa583.
4. 2. Ondoa P, Kebede Y, Loembe MM, Bhiman JN, Tessema SK, Sow A, Sall AA,
5. Nkengasong J. 2020. COVID-19 testing in Africa: lessons learnt. Lancet Microbe 1:e103-

377 e104.

1. 3. Carter C TLAN, Notter J. 2020. COVID-19 disease: perspectives in low- and middle-
2. income countries. Clinics in Integrated Care 1.
3. 4. Giri A, Rana, DR. 2020. Charting the challenges behind the testing of COVID-19 in
4. developing countries: Nepal as a case study. Biosafety and Biohealth 2:53-56.
5. 5. van Bockel D, Munier CML, Turville S, Badman SG, Walker G, Stella AO, Aggarwal A,
6. Yeang M, Condylios A, Kelleher AD, Applegate TL, Vallely A, Whiley D, Rawlinson
7. W, Cunningham P, Kaldor J, Guy R. 2020. Evaluation of Commercially Available Viral



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. Transport Medium (VTM) for SARS-CoV-2 Inactivation and Use in Point-of-Care
2. (POC) Testing. Viruses 12.
3. 6. Welch SR, Davies KA, Buczkowski H, Hettiarachchi N, Green N, Arnold U, Jones M,
4. Hannah MJ, Evans R, Burton C, Burton JE, Guiver M, Cane PA, Woodford N, Bruce
5. CB, Roberts ADG, Killip MJ. 2020. Analysis of Inactivation of SARS-CoV-2 by
6. Specimen Transport Media, Nucleic Acid Extraction Reagents, Detergents, and Fixatives.
7. J Clin Microbiol 58.
8. 7. Maytum R. 2020. Protecting and testing-more to be learned from Ebola. BMJ

393 369:m1618.

1. 8. Pan American Health Organization WHO. General Procedures for Inactivation of
2. Potentially Infectious Samples with Ebola Virus and Other Highly Pathogenic Viral
3. Agents. https:/[/www.paho.org/hq/dmdocuments/2014/2014](http://www.paho.org/hq/dmdocuments/2014/2014-cha-procedures-inactivation-)-[cha-procedures-inactivation-](http://www.paho.org/hq/dmdocuments/2014/2014-cha-procedures-inactivation-)
4. ebola.pdf. Accessed
5. 9. Blow JA, Dohm DJ, Negley DL, Mores CN. 2004. Virus inactivation by nucleic acid
6. extraction reagents. J Virol Methods 119:195-8.
7. 10. Kochel T, Kocher, GA., Ksiazek, TG., Burans JP. 2017. Evaluation of TRIzol LS
8. Inactivation for Viruses. Applied Biosafety 22:52-55.
9. 11. Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, Queen K, Tao Y, Paden
10. CR, Zhang J, Li Y, Uehara A, Wang H, Goldsmith C, Bullock HA, Wang L, Whitaker B,
11. Lynch B, Gautam R, Schindewolf C, Lokugamage KG, Scharton D, Plante JA,
12. Mirchandani D, Widen SG, Narayanan K, Makino S, Ksiazek TG, Plante KS, Weaver
13. SC, Lindstrom S, Tong S, Menachery VD, Thornburg NJ. 2020. Severe Acute



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United
2. States. Emerg Infect Dis 26:1266-1273.
3. 12. Mashock MJ, Faron ML, Buchan BW, Ledeboer NA. 2017. Evaluation of Copan
4. FecalSwab as Specimen Type for Use in Xpert C. difficile Assay. J Clin Microbiol

411 55:3123-3129.

1. 13. Richard-Greenblatt M, Rutherford C, Luinstra K, Cardenas AM, Pang XL, Jayaratne P,
2. Smieja M. 2020. Evaluation of the FecalSwab for Stool Specimen Storage and Molecular
3. Detection of Enteropathogens on the BD Max System. J Clin Microbiol 58.
4. 14. Kiyaga C, Sendagire H, Joseph E, McConnell I, Grosz J, Narayan V, Esiru G, Elyanu P,
5. Akol Z, Kirungi W, Musinguzi J, Opio A. 2013. Uganda's new national laboratory
6. sample transport system: a successful model for improving access to diagnostic services
7. for Early Infant HIV Diagnosis and other programs. PLoS One 8:e78609.
8. 15. Sutcliffe CG, van Dijk JH, Hamangaba F, Mayani F, Moss WJ. 2014. Turnaround time
9. for early infant HIV diagnosis in rural Zambia: a chart review. PLoS One 9:e87028.
10. 16. Chin AWH, Chu JTS, Perera MRA, Hui KPY, Yen HL, Chan MCW, Peiris M, Poon
11. LLM. 2020. Stability of SARS-CoV-2 in different environmental conditions. Lancet
12. Microbe 1:e10.
13. 17. Wang XW, Li JS, Jin M, Zhen B, Kong QX, Song N, Xiao WJ, Yin J, Wei W, Wang GJ,
14. Si BY, Guo BZ, Liu C, Ou GR, Wang MN, Fang TY, Chao FH, Li JW. 2005. Study on
15. the resistance of severe acute respiratory syndrome-associated coronavirus. J Virol

427 Methods 126:171-7.



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

1. 18. Sizun J, Yu MW, Talbot PJ. 2000. Survival of human coronaviruses 229E and OC43 in
2. suspension and after drying onsurfaces: a possible source ofhospital-acquired infections.
3. J Hosp Infect 46:55-60.
4. 19. Zasada AA, Zacharczuk K, Woznica K, Glowka M, Ziolkowski R, Malinowska E. 2020.
5. The influence of a swab type on the results of point-of-care tests. AMB Express 10:46.
6. 20. Rodino KG, Espy MJ, Buckwalter SP, Walchak RC, Germer JJ, Fernholz E, Boerger A,
7. Schuetz AN, Yao JD, Binnicker MJ. 2020. Evaluation of Saline, Phosphate-Buffered
8. Saline, and Minimum Essential Medium as Potential Alternatives to Viral Transport
9. Media for SARS-CoV-2 Testing. J Clin Microbiol 58.
10. 21. Rogers AA, Baumann RE, Borillo GA, Kagan RM, Batterman HJ, Galdzicka MM,
11. Marlowe EM. 2020. Evaluation of Transport Media and Specimen Transport Conditions
12. for the Detection of SARS-CoV-2 by Use of Real-Time Reverse Transcription-PCR. J
13. Clin Microbiol 58.
14. 22. Garnett L, Bello A, Tran KN, Audet J, Leung A, Schiffman Z, Griffin BD, Tailor N,
15. Kobasa D, Strong JE. 2020. Comparison analysis of different swabs and transport
16. mediums suitable for SARS-CoV-2 testing following shortages. J Virol Methods

444 285:113947.

445 23. Mostafa HH, Fissel JA, Fanelli B, Bergman Y, Gniazdowski V, Dadlani M, Carroll KC,

446 Colwell RR, Simner PJ. 2020. Metagenomic Next-Generation Sequencing of

447 Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients.

448 mBio 11.

449

450



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

# FIGURE 1

1. **eNAT inactivation of SARS-CoV-2.** Infectious SARS-CoV-2 was quantified by viral plaque
2. assay on Vero-E6 cells following incubation with eNAT or DMEM for 10 min at room
3. temperature to determine the efficacy of eNAT for inactivating SARS-CoV-2. Analysis of eNAT
4. inactivation was performed using two sample types. (A) Swabs were inoculated with infectious
5. SARS-CoV-2 stock (~100µL; stock, 2.3 x 107 PFU/mL) or DMEM and were placed into
6. transport tubes containing 1mL of eNAT or DMEM; or (B) Equal volumes of SARS-CoV-2
7. stock (2.3 x 107 PFU/mL) or DMEM was combined with eNAT or DMEM (final volume of
8. 200µl) in the absence of a swab. Bars are representative of experimental triplicates (mean ±
9. standard deviation). Data displayed is from a single representative experiment of three
10. independent experiments. Dotted line indicates limit of detection of 500 PFU/mL due to eNAT
11. lysis of the Vero E6 cells at the lowest dilution (10-1). Abbreviations: ND, not detected; LoD,
12. limit of detection; DMEM, Dulbecco’s Modified Eagle Medium.

# FIGURE 2

1. **Effect of alternative transport media storage time and temperature on the molecular**

# detection of SARS-CoV-2 nucleic acid in contrived nasopharyngeal swab specimens.

1. Transport media was stored at 4°C (A), 22-25°C (B), or 35°C (C) for 14 days. SARS-CoV-2 *CT*
2. values for each sample were determined at baseline and days 1, 3, 7, and 14. Change in *CT* value
3. from baseline (Δ*CT*) was calculated and plotted. Bars are representative of experimental
4. triplicates and presented as mean Δ*CT* values ± standard deviation from baseline. Loss in sample
5. sensitivity from baseline is plotted as positive value. Δ*CT* values >1 are considered a significant
6. change from baseline. Abbreviations: NaCl, 0.9% saline; PBS, phosphate buffered saline; VTM,
7. viral transport medium.

Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

474

22



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

# TABLE 1

Accuracy of SARS-CoV-2 detection in 20 contrived eNAT and VTM NP swab sample pairs using the Cepheid Xpert Xpress SARS-CoV-2 assay.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Results (no.) for indicated transport medium** | | | | **% (95% CI)** | |
| Total samples tested | eNAT  positive | VTM positive | Total samples negative | PPA | NPA |
| 20 | 15 | 15 | 5 | 100  (78.2-100) | 100  (47.8-100) |

Abbreviations: VTM, viral transport medium; CI, confidence interval; PPA, positive percent agreement; NPA, negative percent agreement.



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

# TABLE 2

Individual C*T* values for matched SARS-CoV-2 positive NP swab sample pairs and interassay C*T* value differences determined by the Cepheid Xpert Xpress SARS-CoV-2 assay.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sample #** | **C*T* Value** | | | | **Difference in C*T* values** | |
|  | E gene | | N2 gene | | E gene | N2 gene |
|  | eNAT | VTM | eNAT | VTM |  |  |
| **1** | 20.6 | 21.2 | 23.2 | 24.0 | -0.6 | -0.8 |
| **2** | 33.2 | 34.7 | 36.5 | 37.0 | -1.5 | -0.5 |
| **3** | 21.1 | 21.2 | 23.6 | 23.7 | -0.1 | -0.1 |
| **4** | 26.0 | 26.3 | 28.5 | 28.8 | -0.3 | -0.3 |
| **5** | 29.8 | 30.1 | 31.8 | 32.8 | -0.3 | -1.0 |
| **6** | 25.3 | 23.7 | 27.4 | 25.8 | 1.6 | 1.6 |
| **7** | 29.0 | 29.7 | 30.7 | 31.8 | -0.7 | -1.1 |
| **8** | 30.4 | 30.3 | 33.2 | 33.1 | -0.1 | -0.1 |
| **9** | 30.3 | 31.1 | 32.8 | 33.4 | -0.8 | -0.6 |
| **10** | 35.0 | 33.6 | 36.9 | 36.3 | 1.4 | 0.6 |
| **11** | 18.4 | 19.2 | 20.7 | 21.7 | -0.8 | -1.0 |
| **12** | 35.1 | 35.2 | 38.0 | 39.4 | -0.1 | -1.4 |
| **13** | 31.9 | 32.3 | 35.2 | 35.5 | -0.4 | -0.3 |
| **14** | 31.1 | 32.3 | 33.2 | 34.6 | -1.2 | -1.4 |
| **15** | 32.8 | 33.4 | 35.7 | 36.4 | -0.6 | -0.7 |



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

**TABLE 3**


Effect of eNAT on analytical sensitivity of the Cepheid Xpert Xpress SARS-CoV-2 assay.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **SARS-CoV- Media C*T* Value Mean C*T* Mean C*T* No. Positive 2 (cp/mL) E gene N2 gene Targets** | | | | | | | | | | |
|  |  |  | E gene |  |  | N2 gene |  |  |  |  |
|  |  | 1 | 2 | 3 | 1 | 2 | 3 |  |  |  |
| **500** | VTM | 34.2 | 35.2 | 35.8 | 37.6 | 38.7 | 38.5 | 35.1 | 38.2 | 6/6 |
|  | eNAT | 34.2 | 34.3 | 35.0 | 38.0 | 37.2 | 37.8 | 34.5 | 37.6 | 6/6 |
| **250** | VTM | 36.7 | 37.1 | 35.4 | 38.0 | 38.1 | 39.9 | 36.4 | 38.7 | 6/6 |
|  | eNAT | 35.7 | 35.4 | 35.6 | 38.7 | 38.2 | 37.8 | 35.6 | 38.2 | 6/6 |
| **125** | VTM | 37.2 | 36.1 | 36.2 | 41.4 | 39.1 | 39.3 | 36.5 | 39.9 | 6/6 |
|  | eNAT | 36.8 | 35.3 | 36.5 | 40.8 | 40.2 | 40.8 | 36.2 | 40.6 | 6/6 |
| **25** | VTM | ND | 38.6 | ND | ND | 40.6 | 41.1 | - | - | 3/6 |
|  | eNAT | 38.6 | ND | 37.6 | ND | 39.9 | 42.0 | - | - | 4/6 |

Abbreviations: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; cp, copies; C*T*, cycle threshold; VTM, viral transport medium; ND, not detected.

1

Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest



Downloaded from <http://jcm.asm.org/> on February 12, 2021 by guest

